Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394. N Engl J Med. 2024. PMID: 39231341 Clinical Trial.
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials.
Zoghbi M, Patel BA, Roulleaux Dugage M, Mezquita L, Bahleda R, Dufresne A, Brahmi M, Ray-Coquard I, Pautier P, Blay JY, Le Cesne A, Massard C, Besse B, Auclin E, Nassif Haddad EF. Zoghbi M, et al. Among authors: pautier p. Cancers (Basel). 2024 Dec 3;16(23):4053. doi: 10.3390/cancers16234053. Cancers (Basel). 2024. PMID: 39682239 Free PMC article.
Doxorubicin-Trabectedin in Leiomyosarcoma. Reply.
Pautier P, Blay JY, Duffaud F. Pautier P, et al. N Engl J Med. 2024 Nov 28;391(21):2058. doi: 10.1056/NEJMc2412479. N Engl J Med. 2024. PMID: 39602639 No abstract available.
[Practical application of the 2023 FIGO classification for endometrial cancer].
Grosse S, Genestie C, Scherier S, Maulard A, Pautier P, Leary A, Michels J, Espenel S, Dabreteau T, Morice P, Gouy S. Grosse S, et al. Among authors: pautier p. Bull Cancer. 2024 Nov 13:S0007-4551(24)00339-4. doi: 10.1016/j.bulcan.2024.09.004. Online ahead of print. Bull Cancer. 2024. PMID: 39542783 French.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
370 results